Commentary
Video
Author(s):
Samuel Cytryn, MD, and David B. Zhen, MD, on 4-year data from CheckMate 649 for nivolumab plus chemotherapy in first-line advanced gastric/GEJ cancer.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
177Lu-edotreotide Improves PFS in Grade 1/2 GEP-NETs in Phase 3 COMPETE Trial
Blinatumomab-Based Regimens Enhance and Refine the B-ALL Treatment Paradigm: With Ryan Cassaday, MD
Encorafenib Combination Approval Paves the Way Forward in BRAF V600E–Mutated CRC
FDA Approval Insights: Zanidatamab in Pretreated, HER2+ Biliary Tract Cancer
Camrelizumab/Nab-POF Combo Increases R0 Resection Rates in Gastric/GEJ Cancer
Neoadjuvant SCRT Plus Cadonilimab/Chemo Meets pCR End Point in pMMR/MSS Rectal Cancer
OS With Chemotherapy Is Linked With Baseline Geriatric, QOL Factors in Metastatic Pancreatic Cancer
Bezuclastinib Plus Sunitinib Elicits Preliminary Activity, Is Safe in Pretreated GIST
Post-Chemotherapy ctDNA Status May Support Organ Preservation Decisions in Rectal Cancer
Adagrasib/Cetuximab Maintains Efficacy in KRAS G12C–Mutated Advanced mCRC
Tissue-Based NGS May Help Determine Relevant Gene Copy Number Gain Cutpoint for HER2/KRAS/MET in NSCLC
Routine Intraoperative Frozen Section Represents a "Very Costly" Soft Tissue Sarcoma Procedure
Watson Unpacks the Potential Clinical Impact of High-Level MET, HER2, and KRAS Amplifications in NSCLC